BioSolveIT GmbH and Proteros biostructures GmbH has announced that they have been awarded a three-year development grant from the German Federal Ministry of Education and Research (BMBF), through its BioChance programme. With the FragScreen project, the German ministry supports the development of fragment-based screening technologies.
The objective of this project is to develop and validate an integrated experimental and computational approach to determine binding of low-molecular weight compounds and molecular probes.
Both companies will work in partnership with the world-renowned research group of Prof. Dr. Gerhard Klebe at the University of Marburg. The consortium is completed by two Top25 global pharmaceutical companies which will contribute to the project from the perspective of the industry requirements.
The award highlights the German government’s recognition of the need to build joint development teams between leading academic institutions and industrial partners small and large to bridge the gap between the research lab and the marketplace, stimulating prosperity through innovation.